Celon Pharma SA (8RP) Stock Statistics & Valuation Metrics

Celon Pharma SA has a market cap or net worth of €284.26M. The enterprise value is €1.72B.

Celon Pharma SA has 53,856,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Celon Pharma SA’s return on equity (ROE) is -0.06 and return on invested capital (ROIC) is -7.63%.

The current PE Ratio of Celon Pharma SA is -28.61. Celon Pharma SA’s PEG ratio is -0.09.

In the last 12 months, Celon Pharma SA had revenue of 213.92M and earned -28.12M in profits. Earnings per share was -0.55.

In the last 12 months, operating cash flow was -17.37M and capital expenditures -15.64M, giving a free cash flow of -33.01M billion.

Celon Pharma SA pays an annual dividend of €0.018, resulting in a dividend yield of 0.37%

Celon Pharma SA upcoming earnings date is Sep 17, 2025, TBA (Confirmed).

Celon Pharma SA as a current ratio of 2.20, with Debt / Equity ratio of 5.59%

In the past 12 months, Celon Pharma SA has paid 8.16M in taxes.

Celon Pharma SA EV to EBITDA ratio is 24.39, with an EV/FCF ratio of -19.40.

Celon Pharma SA has €103.28M in cash and marketable securities with zł14.32M in debt, giving a net cash position of -€88.96M billion.

Gross margin is 58.95%, with operating margin of -12.73%, and net profit margin of -13.15%.

The average price target for Celon Pharma SA is ―, which is 11.43% higher than the current price. The consensus rating is ―